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Summary 
Clozap ine  i s  an ant ipsychot ic  drug  which  i s  unusua l  in  that  i t  
has  no dopamine receptor -b lock ing  ac t iv i ty .  P rev ious  s tud ies  
gave  conf l i c t ing  resu l t s  whether  admin is t ra t ion  o f  c lozap ine  
induces  hyperpro lac t inemia .  
In  the  present  s tudy  i t  was shown that  a wide concent ra t ion  
range  o f  c lozap ine  does  not in ter fe re  w i th  dopamine-med ia ted  
inh ib i t ion  o f  p ro lac t in  (PRL) secret ion  by normal  cu l tu red  ra t  
p i tu i ta ry  ce l l s .  Th is  in  cont ras t  to  o ther  neuro lept i cs ,  l i ke  
ha loper ido l  and t r i f luoperaz ine .  C lozsp lne  does  a l so  not  
antagon ize  norep lnephr lne -med ia ted  inh ib i t ion  of  PRL secret ion .  
C lozap ine  exer ts  a t  mic romolar  concent ra t ions  a d i rec t  
inh ib i to ry  ac t ion  on PRL re lease  by cu l tu red  normal  ra t  
p i tu i ta ry  ce l l s .  In  cu l tu red  ra t  p i tu i ta ry  tumor ce l l s ,  these  
:~ h igh  concent ra t ions  o f  c lozap ine  d i rec t ly  inh ib i t  PRL re lease  
as  we l l  as  the  DNA content  of  the  ce l l s ,  suggest ing  a d i rec t  
ant imi to t i c  ac t ion .  In  th i s  model c lozap lne  was about  5-10 
t imes  less  potent  than  t r i f luoperaz ine .  C lozap ine  and 
t r l f luoperaz lne  exer t  an add i t ive  inh ib i to ry  ac t ion  both  on PRL 
re lease  and on the  DNA content  of  the  p i tu i ta ry  tumor ce l l s .  
I t  i s  conc luded  that  c lozap ine  does  not  in ter fe re  a t  the  
p i tu i ta ry  leve l  w i th  dopamlne-med ia ted  inh ib i t ion  o f  PRL 
re lease .  At mic romolar  concent ra t ions  c lozap ine  may act  on 
lac to t rophs  as  a ca lmodu l in - inh ib i to r .  These  observat ions  
suggest  that  the  t rans ient  PRL- re leas ing  e f fec ts  which have 
been observed  in  both  an ima l  and human s tud ies  a f te r  c lozap ine  
admin is t ra t ion  a re  med ia ted  v ia  supra -p i tu i ta ry  ac t ions  of  the  
drug .  
C lozap ine ,  a d ibenzap ine  der ivat ive ,  i s  an ant ipsychot ic  drug  which i s  
unusua l  in  that  i t  has  no typ ica l  ant idopaminerg ic  p ro f i l e  (1 -4 ) .  I t s  s t rong  
ant ipsychot ic  and sedat ive  ac t ions  a re  accompanied  w i th  on ly  mi ld  ext ra -  
pyramida l  s ide  e f fec ts .  The drug  was recent ly  found to  be espec ia l l y  success fu l  
in  t reatment - res i s tant  sch izophren ics  (5) .  Th is  las t  observat ion  probab ly  means 
that  c lozap ine  in  the  near  fu ture  w i l l  be par t  o f  the  therapeut ic  armament of  
psych ia t r i c  ins t i tu t ions  th roughout  the  wor ld ,  desp i te  o ther  potent ia l  severe  
s ide -e f fec ts ,  l i ke  an inc reased  r i sk  of  agranu locytos i s  (6 ) .  
One o f  the  commonly occur r ing  s lde -e f fec ts  o f  the  chron ic  use  of  neuro lept i c  
d rugs  i s  hyperpro lac t inemia .  Th is  o f ten  causes  ga lac tor rhea ,  amenor rhea  nd /or  
loss  of  l i b ido  (7 ) .  However,  p rev ious  repor ts  w i th  regard  to  the  e f fec ts  of  
c lozap lne  on pro lac t ln  (PRL) re lease  were inconc lus ive  in  that  the  drug  causes  
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hyperpro lact inemia in rats (8-10), but not, or only to a minimal extent in man 
(11-15). The mechanism of action of the c lozapine-mediated increase in 
c i rculat ing PRL levels in rats is unclear (8). The compound was shown to 
displace SH-dihydroergocrypt ine binding from bovine anter ior pituitary 
membranes (16), and ~H-spiroper idol  binding from rat pituitary membranes (17), 
but in both studies micromolar  concentrat ions of c lozapine were needed. In the 
present study we evaluated whether clozapine exerts a direct act ion on PRL 
release at the pitu i tary level. We found that the drug does not affect 
dopamine-mediated inhibit ion of PRL secretion, but acts at high concentrat ion 
probably as a calmodul in inhibitor. 
Mater ia ls  and Methods 
Male Rp rats or female Rp rats (in any stage of the estrous cycle), 
obtained from T.N.O., Ri jswijk, The Netherlands, weighing 180-200 g were used 
for the preparat ion of cultured normal pituitary cells. The isolat ion methods 
have been descr ibed in detai l  by Hofland et al (18). The culture medium used in 
all exper iments was phenol red-free Eagle's Minimal Essential  Medium with 
Ear le 's  salts (MEM) supplemented with I% MEM non-essent ia l  amino acids, sodium 
pyruvate (I mmol/l) ,  penic i l l in  (10 s U/l), streptomycin (I00 mg/l), fungizone 
(0.5 mg/l), L -g lutamin (2 mmol/l),  sodium bicarbonate (2.2 g/l), and 10% fetal 
cal serum which had been treated with dextran-coated charcoal. The cells were 
cultured at a density of I0" cells per well  in 1 ml of culture medium in 48- 
wel l  plates. On day 4 of culture the medium was changed and after an addit ional  
medium change on day 7 of culture 4 hr incubations were carr ied out. 
Female Buffalo rats (R.B. I . ,Ri jswi jk,The Netherlands),  weighing 150-170 g were 
inoculated subcutaneously between the scapula with a suspension of the 
transplantable PRL-secret ing rat pituitary tumor 7315h, as descr ibed in detai l  
e lsewhere (19). The 7315b tumor is a pure PRL secret ing pi tu i tary tumor, which 
was der ived from the mixed ACTH/PRL secret ing pitu i tary tumor 7315a. The 7315b 
tumor has dopamine receptors, but is resistant to dopaminergic inhibit ion, 
presumably because of an intracel lular defect. Four weeks after inoculat ion of 
the tumor cell suspension a tumor of approximately 20 cm m had grown dorsal ly  on 
the animals. 7315b Pi tu i tary tumor cells were isolated by mechanical  
dispersion. In order to separate vital  cells from non-vital  cells the 
suspension was layered on F icol l - Isopaque (density 1.077 g/ml; prepared by the 
Di jkzigt Hospital  Pharmacy, Rotterdam, The Netherlands) and centr i fuged at I000 
x g for 20 min. The interphase containing vital  cells was col lected and washed 
twice. F inal ly the cells were resuspended and cultured at a density of 25.000 
cells per wel l  in 1 ml of culture medium, consist ing of MEM with 10% untreated 
fetal calf serum. On day 6 of culture the media plus cells were col lected and 
stored at -20°C unti l  analysis. 
Dopamine, norepinephr ine and tr i f luoperazine were purchased 
chemical company (St Louis, Missouri,  USA). Clozapine was a gift 
(Basel, Switzerland). 
from Sigma 
from Sandoz 
Rat PRL concentrat ions in the culture media were measured by a double antibody 
RIA using mater ia ls  and protocols suppl ied by the d istr ibut ion off icer of the 
NIADDK. Al l  results are expressed in rat PRL reference preparat ion (RP-I). The 
DNA content of the tumor cells was determined as descr ibed in detai l  elsewhere 
(20). The method is based on a DNA dependent f luorescence enhancement of a 
f luorochrome. F luorescence of experimental  samples was referenced to a 
standard curve of calf thymus DNA (type II, no-D-3636; Sigma). The data are 
expressed as means ± SEM. 
The stat ist ical  s ignif icance of the di f ferences between mean values was 
determined using analysis of var iance (ANOVA). When signif icant overal l  effects 
were obtained by ANOVA, mult ip le comparisons were made with the Newman-Keuls  
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Fig.  1 
The e f fec ts  o f  dopamine,  norep inephr ine  and c lozap ine  on PRL re lease  
by normal cultured rat p i tu i tary cells. The cells had been 
precul tured for 3 days. Incubation time 4 h. Mean ± SEM (n=4 wel ls 
per group). 
test. Al l  data shown represent the results of at least three exper iments which 
gave similar results. 
Results 
The effects of dopamine, norepinephr ine and clozapine on PRL release by 
normal cultured rat p i tu i tary cells are shown in £ig. I. All three compounds 
inhibited PRL release in a dose-dependent manner, the IC~o for dopamine, 
norepinephr ine and clozapine being 30 nM, 400 nM and 6 ~M, respectively. 
The inhib i t ion of PRL secret ion by dopamine (50-500 riM) was not antagonized by 
a wide dose-range of 1 nM - 1 ~M clozapine, whi le in the same experiments the 
dopamine-receptor  antagonist  haloperldol  (5 nM) at least part ia l ly  neutral ized 
dopamine-medlated inhibit ion of PRL release (Table I). 
The inhibi t ion of PRL secret ion by norepinephr lne (I00 nM- 1 ~M) was not 
af fected by a wide dose-range of 1 nM - I~  clozapine. The inhibitory effect of 
norepinephr ine on PRL release was attenuated by haloperidol  (5 nM), however, 
but not by fencolamine (I00 nM - I0 ~d~), prazosine (I00 nM-  I0 ~M) or 
propranolo l  (i00 nM-10 ~M; data not shown). 
Thereafter  we invest igated the effects of c lozapine on cultured PRL-secret ing 
p i tu i tary tumor cells prepared from the transplantable rat p i tu i tary tumor 
7315b. As a compar ison the effects of t r i f luoperazine were also investigated. 
Both c lozaplne and tr i f luoperazlne inhibited PRL release by the cultured tumor 
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Fig. 2 
The effects of clozapine and trifluoperazine on PRL release (left) 
and the DNA content (right) of cultured cells prepared from the 
transplantable 7315b rat pituitary tumor. Culture time was 6 days. 
Mean ± SEM (n=4 dishes wells group). 
cells and the DNA content of the cells after 6 days of culture in a dose- 
dependent manner (fig. 2). Clozapine and trifluoperazine exerted similar PRL 
release-inhibitory and antimitotic effects, trifluoperazine being 5-10 times 
more potent than clozapine. 
In  a f ina l  exper iment  ( tab le  I I )  i s  was shown that  both  compounds exer t  
s imi la r  ac t ions  in  th i s  tumor ce l l  model ,  because  the  combinat ion  o f  5 ~M 
c lozap ine  and I ~4 t r i f luoperaz ine  inh ib i ted  PRL re lease  and the  DNA content  
o f  the  ce l l s  in  an add i t ive  fash ion  ( tab le  I I ) .  
D i scuss ion  
The ant ipsychot ic  e f f i cacy  o f  the  neuro lept i c  c lass  of  d rugs  i s  c lose ly  
cor re la ted  to  antagon ism of  the  D-2 dopamine receptor  (7 ,21-23) .  The 
ant ipsychot ic  ac t ion  o f  these  drugs  may be med ia ted  pr imar i l y  a t  D-I 
dopaminerg ic  receptors  in  the  l lmb ic  a rea ,  whereas  ac t ion  a t  s t r ia ta l  D-2 
receptors  and/or  ha loper ido l - sens i t i ve  s igma receptors  may be respons ib le  fo r  
ext rapyramida l  s ide -e f fec ts  wh i le  the i r  ac t ion  a t  the  p i tu i ta ry  D-2 receptors  
causes  hyperpro lac t inemia  which o f ten  resu l t s  in  ga lac tor rhea ,  amenor rhea  
and/or  loss  o f  l i b ido  (7 ,23 ,24) .  
C lozap ine  i s  a p iperaz ine  der ivat ive  of  the  d ibenzod iazep ine  group ,  w i th  a 
s t ron  E ant lpsychot ic  and sedat ive  ac t ion  (1 -5 ) .  I t  has  a weak D-I  dopamine 
receptor  b lock ing  effect, with spec ia l  affinity to mesolimbic areas, while it 
also has strong anti-noradrenergic, anti-histaminergic, and anti-cholinergic 
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TABLE I 
The effects of c lozapi ine and haloperidol  on dopamine-mediated inhibit ion of 
PRL release by normal cultured female rat pituitary cells. 
PRL re lease  
as  a percentage  
cont ro l  
of 
dopamlne (500 mM) 52.9 ± 3.1- 
dopamine + c lozapine (I riM) 45.3 ± 3.1- 
dopamine + c lozaplne (I0 nM) 50.0 ± 1.6" 
dopamine + c lozapine (100 riM) 49.1 ± 2.1- 
dopamine + c lozapine (I ~M) 46.8 ± 3.4- 
dopamine + haloper idol  (5 nM) 74.8 ± 1.4 "-b 
The cel ls had been precultured for 3 days. Incubation time 4 h. 
Mean ± SEM (n= 4 wel ls per group) 
-p<0.01 vs control  
bp<0.01 vs dopamine (500 nM) 
TABLE II 
The e f fec t  o f  c lozap ine ,  t r i f luoperaz ine  and  the i r  combinat ion  on  PRL re lease  
and  the  DNA content  o f  cu l tured  7315b ra t  p i tu i ta ry  tumor  ce l l s .  
PRL release 
(ng/10 s cel ls/6 days) 
DNA content 
(ng/well) 
control  177.4 ± 2.5 
c lozapine (5 ~M) 75.0 ± 3.9 b 
t r i f luoperaz ine (i ~M) 101.3 ± 2.2 b 
c lozapine+tr i f luoperaz lne 40.1 ± 2.6" 
incubat ion time 6 days; mean ± SEM (n=4 wel ls/group) 
"p<0.05 vs control  bp<0.01 vs control 
°p<0.01 vs c lozapine and tr l f luoperazine separately 
747.5 ± 39.3 
442.8 ± 103.1- 
511.8 ± 30.3" 
155.3 ± 14.3 ° 
effects (1-5). C lozapine does not produce extrapyramidal  syndromes and was 
recent ly  shown to be very effect ive in treatment-resistant schizophrenics (5). 
Previous studies on the effects of c lozapine on PRL release have been 
confl ict ing. The drug markedly increased serum PRL levels in rats, when 
injected intraper i toneal ly  in doses of 5-100 mg/kg (8-10). The PRL-re leasing 
effect of c lozapine was only 20-50% of that of chlorpromazine, however. In 
pat ients treated with 200-600 mg clozapine per day PRL levels were reported to 
be moderate ly  increased, especial ly during the first 4 h after drug 
admin is t rat ion (II,12), but not thereafter (11,15,22). Chronic therapy of 
psychotic pat ients for 2-4 weeks with 600 mg clozapine per day did not increase 
the PRL levels of the cerebrospinal  f luid (12). So, c lozapine is d ist inct ly 
less potent in its in vivo effects on PRL secretion in both rat and man, but 
its mechanism of act ion is unexplained. Meltzer et al (8) suggested that the 
increase in serum PRL levels are attr ibuted to c lozapine's abi l i ty  to produce 
dopamlne blockade at the pituitary level or to inhibit nerve impulse-dopamine 
release or both. Indeed clozapine was found to displace SH-dihydroergocrypt ine 
binding from bovine anter ior pituitary membranes (16) and ~H-splroper ldol  from 
rat p i tu i tary membranes (17), but the ICso's of c lozapine were about I000 nM in 
the former and 1320 ± 86 nM in the latter study. 
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Our present  s tud ies  might  he lp  to  unders tand  the  seeming ly  d i sc repant  p rev ious  
observat ions .  C lozap ine  does  not  in ter fe re  w i th  the  dopamine-med ia ted  
inh ib i t ion  o f  PRL re lease  by cu l tu red  ra t  p i tu i ta ry  ce l l s .  Th is  in  cont ras t  
w i th  the  ac t ion  o f  neuro lept i cs  l i ke  ha loper ido l  and t r i f luoperaz ine  which 
b lock  the  dopamine e f fec t  a t  concent ra t ions  in  the  nanomolar  range  (25) .  
Norep inephr ine  inh ib i t s  PRL re lease  by lac to t rophs  v ia  i t s  d i rec t  e f fec ts  a t  
the  dopamine receptor  (16) .  Th is  assumpt ion  i s  under l ined  by our  observat ion  
that  the  norep inephr ine -med ia ted  inh ib i t ion  o f  PRL re lease  was antagon ized  by 
ha loper ido l ,  but  not  by prazos ine ,  fento lamine  and proprano lo l .  C lozap ine  d id  
not  reverse  norep inephr ine - induced  inh ib i t ion  o f  PRL re lease ,  fu r ther  exc lud ing  
the possibil ity that it causes hyperprolactinemia via a blockade of a-receptors 
at the pituitary level. 
F ina l ly  i t  was shown that  a t  mic romolar  concent ra t ions ,  c lozap ine  d i rec t ly  
inh ib i ted  PRL re lease  by normal  and tumorous  p i tu i ta ry  ce l l sp  as  we l l  as  
mi tos i s  o f  the  tumor ce l l s .  In  th i s ,  i t s  ac t ions  were qu i te  s imi la r  (and 
add i t ive )  to  those  of  h igh  concent ra t ions  o f  t r i f luoperaz ine .  I t  has  been 
prev ious ly  shown that  phenoth iaz ines ,  butyrophenores  and t r i cyc l i c  
ant idepressants  b ind  to  and inact ivate  ca lmodu l in  in  the  presence  of  ca lc ium in  
several model systems (26,27). The inactivation of calmodulin by these 
compounds suppresses not only anterior pituitary hormone secretion which is 
dependent on calcium ions (27), but in malignant cells which have been shown 
often to contain elevated calmodulin levels (28), chronic blockade of its 
action results in direct antimitotic effects. In these studies trifluoperazine 
has been most often used: micromolar concentrations of the drug inhibited the 
growth of human breast and ovarian cancer cells (29,30). A similar mechanism of 
action may explain the effects of high concentrations of clozapin on normal and 
tumorous PRL secretion. 
In conclusion, we showed that clozapine does not interfere at the pituitary 
level with dopamine-mediated inhibition of PRL release. Its binding to rat and 
bov ine  p i tu i ta ry  dopamine receptors  i s  p robab ly  o f  no phys io log ica l  
s ign i f i cance ,  because  the  concent ra t ions  o f  c lozap ine  needed fo r  a 50~ 
d isp lacement  in  p i tu i ta ry  membrane preparat ions  a re  in  the  mic romolar  range  and 
we showed that  a t  these  concent ra t ions  the  drug  exer ts  in  in tac t  ce l l s  on ly  
inh ib i t ion  of  PRL re lease ,  p robab ly  v ia  an inh ib i t ion  of  ca lmodu l in  ac t ion .  Our 
observat ions  suggest  that  the  t rans ient  PRL re leas ing  e f fec t  which has  been 
observed  a f te r  in t raper i tonea l  in jec t ion  of  c lozap ine  in  ra ts  and on ly  to  a 
min ima l  extent  a f te r  o ra l  admin is t ra t ion  in  man, i s  caused  v ia  supra -p i tu i ta ry  
ac t ions  which  might  invo lve  bra in  sero ton in ,  norep inephr ine  and/or  
acety lcho l ine  metabo l i sm,  or an ind i rec t  change in  the  dopaminerg ic  ac t iv i ty  of  
the  tubero - in fund ibu la r  neurons .  
Re ferences  
I. H.R. BURKI, W. RUCH, and H. ASPER, Psychopharmacol. 4--1 27-33 (1975). 
2. G. SEDVALL and A. NYBACK, Isr. J. Med. Sci. 9 24-30 (1973) (Suppl.). 
3. J.E. LEYSEN, In: Usden E, Dab1 S, Gram LF Lingjaerde O, eds. Clinical 
Pharmacology and psychiatry. Neuroleptics and antidepressant research. 
London: MacMillan Press 1981 35-61. 
4. Th.F. SEEGER, L. THAL and E.L. GARDNER, Psychopharmacology ?6 182-187 
(1982). 
5. J. KANE, P. HONIGFELD, J. SINGER, H. MELTZER and THE CLOZARIL 
COLLABORATIVE'STUDY GROUP, Arch. Gen. Psychiatry 45 789-796 (1988). 
6. S.R. MARDER, Arch. Gen. Psychiatry 4-5 865-867 (1988). 
7. A.I. GREEN and W.A. BROWN, Endocrinol. Metab. Clin. North Am. 17 213-224 
(1988). 
8. H. MELTZER, S. DANIELS and V.S. FANG, Life Sci. 17 339-342 (1975). 
9. W. LOTZ and P. KRAUSE, J. Endocr. 76 507-515 (1978). 
10. S.E. HAYS, R.E. POLAND and R.T. RUBIN, J. Pharmacol. Exp. Ther. 214 362- 
Vol. 46, No. 14, 1990 Clozapine and Prolactln Secretion 1019 
367 (1980).  
11. H.Y MELTZER, R.G. FESSL~R and V.S. FANG, Psychopharmaco l .  54 183-186 
(1977).  
12. G. SEDVALL, L. BJERKENSTEDT, L. LINDSTROM and B. WODE-HELGODT. Life Sci. 
23 425-429 (1978). 
13. H.Y. MELTZER, D.J. GOODE, P.M. SCHYNE, M. YOUNG and V.S. FANG, Amer. J. 
Psychiat. 135 1550-1555 (1979). 
14. N.P.V. NAIR, S.L.P. CERVANTES, R YASSA and H. GUYDA, Neuropsychobiology 
136-142 (1979). 
15. J.M. KANE, T.B. COOPER, E.J. SACHAR, F.S. HALPERN and S. BAILINE, 
Psychopharmaco l . (Ber l . )  73 184-187 (1981).  
16. M.G. CARON, M. BEAULIEU, V. RAYMOND, B. GAGNE, J .  DROUIN, H. J .  LEFKOWITZ 
and F. LABRIE, J .  B io l .  Chem. 25__~3 2244-2253 (1978).  
17. H.Y. MELTZER, R. SO, R . J .  MILLER and V.S. FANG, L i fe  Sc l .  25 573-583 
(1979).  
18. L.J. HOFLAND, P. VAN KOETSVELD, J.W. KOPER, A. DEN HOLDER and S.W.J. 
LABMERTS, Mol. Cell. Endocrinol. 5-4 43-48 (1987). 
19. S.W.J. LAMBERTS, P. UITTERLINDEN and T. VERLEUN, Cancer Res. 4-5 1015 
(1985). 
20. T.R. DOWNS and W..W. WILFINGER, Anal. Biochem. 131 538-547 (1983). 
21. E.J. SACHAR, P.H. GRUEN and N. ALTMAN, Psychopharmacol. Bull. 13 60-61 
(1977).  
22. P.H. GRUEEN, E.J. SACHAR, G. LANGER, N. ALTMAN, M. LEIFER, A. FRANTZ and 
F.S. HALPERN, Arch. Gen. Psychiat. 35 108-116 (1978). 
23. P.H. GRUEN, Med. Clin. N. Amer. 6__2 409-424 (1978). 
24. J.M. WALKER, R.R. MATSUMOTO, W.D. BOWEN, D.L. GANS, K.D. JONES, F.O. 
WALKER, Neurology 38 961-965 (1988). 
25. R.M. MACLEOD, Frontiers in Neuroendocrinol. ~ 169-194 (1976). 
26. R.N. LEVIN and B. WEISS, Mol. Pharmacol. 12 581-589 (1976). 
27. S. TOMLINSON, S. MACNEIL, S.W. WALKER, C.A. OLLIS, J.E. MERRITT and B.L. 
BROUWN, Clin. Sci. 6--6 497-508 (1984). 
28. J.G. CHAFOULEAS, R.L. PARDUE, B.R. BRINKLEY, J.R. DEDMAN and A.R. MEANS, 
Proc. Nat. Acad. Sci. U.S.A. 78 996-1000 (1981). 
29. J-W WEI, R.A. HICKIE and D.J. KLAASSEN, Canc. Chem. Pharmacol. 1186-90  
(1983). 
30. Y. KIKUCHI, I. IWANO and K. KATO, Biochem. Biophys. Res. Comm. 123 385-392 
(1984). 
